Integrating genetics and epigenetics in myelodysplastic syndromes: Advances in pathogenesis and disease evolution

British Journal of Haematology

Volumn 166, Issue 5, 2014, Pages 646-659

  Bravo, Guillermo Montalbán ^a   Lee, Elinor ^b   Merchan, Bryan ^c   Kantarjian, Hagop M ^d   García Manero, Guillermo ^d  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Epigenetics; Genetics; Myelodysplastic syndromes

Indexed keywords

ANIMAL; GENETIC EPIGENESIS; GENETICS; HUMAN; MYELODYSPLASTIC SYNDROME; PATHOLOGY; PROGNOSIS;

ANIMALS; EPIGENESIS, GENETIC; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 84906054823     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12957     Document Type: Article

References (105)

1. Abdel-Wahab, O. & Dey, A. (2013) The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics. Leukemia, 27, 10-15.
2. Abdel-Wahab, O. & Figueroa, M.E. (2012) Interpreting new molecular genetics in myelodysplastic syndromes. Hematology American Society of Hematology Education Program, 2012, 56-64.
3. Abdel-Wahab, O. & Levine, R.L. (2013) Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood, 121, 3563-3572.
4. Abdel-Wahab, O., Mullally, A., Hedvat, C., Garcia-Manero, G., Patel, J., Wadleigh, M., Malinge, S., Yao, J., Kilpivaara, O., Bhat, R., Huberman, K., Thomas, S., Dolgalev, I., Heguy, A., Paietta, E., Le Beau, M.M., Beran, M., Tallman, M.S., Ebert, B.L., Kantarjian, H.M., Stone, R.M., Gilliland, D.G., Crispino, J.D. & Levine, R.L. (2009) Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood, 114, 144-147.
5. Abdel-Wahab, O., Adli, M., LaFave, L.M., Gao, J., Hricik, T., Shih, A.H., Pandey, S., Patel, J.P., Chung, Y.R., Koche, R., Perna, F., Zhao, X., Taylor, J.E., Park, C.Y., Carroll, M., Melnick, A., Nimer, S.D., Jaffe, J.D., Aifantis, I., Bernstein, B.E. & Levine, R.L. (2012) ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell, 22, 180-193.
6. Abrahamsson, A.E., Geron, I., Gotlib, J., Dao, K.H., Barroga, C.F., Newton, I.G., Giles, F.J., Durocher, J., Creusot, R.S., Karimi, M., Jones, C., Zehnder, J.L., Keating, A., Negrin, R.S., Weissman, I.L. & Jamieson, C.H. (2009) Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proceedings of the National Academy of Sciences of the United States of America, 106, 3925-3929.
7. Aimiuwu, J., Wang, H., Chen, P., Xie, Z., Wang, J., Liu, S., Klisovic, R., Mims, A., Blum, W., Marcucci, G. & Chan, K.K. (2012) RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. Blood, 119, 5229-5238.
8. Barski, A., Cuddapah, S., Cui, K., Roh, T.Y., Schones, D.E., Wang, Z., Wei, G., Chepelev, I. & Zhao, K. (2007) High-resolution profiling of histone methylations in the human genome. Cell, 129, 823-837.
9. Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R.L., Neuberg, D. & Ebert, B.L. (2011) Clinical effect of point mutations in myelodysplastic syndromes. New England Journal of Medicine, 364, 2496-2506.
10. Bejar, R., Stevenson, K.E., Caughey, B.A., Abdel-Wahab, O., Steensma, D.P., Galili, N., Raza, A., Kantarjian, H., Levine, R.L., Neuberg, D., Garcia-Manero, G. & Ebert, B.L. (2012) Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. Journal of Clinical Oncology, 30, 3376-3382.
11. Bird, A. (2002) DNA methylation patterns and epigenetic memory. Genes & Development, 16, 6-21.
12. Borthakur, G., Ahdab, S.E., Ravandi, F., Faderl, S., Ferrajoli, A., Newman, B., Issa, J.P. & Kantarjian, H. (2008) Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leukemia & Lymphoma, 49, 690-695.
13. Boultwood, J., Perry, J., Pellagatti, A., Fernandez-Mercado, M., Fernandez-Santamaria, C., Calasanz, M.J., Larrayoz, M.J., Garcia-Delgado, M., Giagounidis, A., Malcovati, L., Della Porta, M.G., Jadersten, M., Killick, S., Hellstrom-Lindberg, E., Cazzola, M. & Wainscoat, J.S. (2010) Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia, 24, 1062-1065.
14. Bracken, A.P., Pasini, D., Capra, M., Prosperini, E., Colli, E. & Helin, K. (2003) EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO Journal, 22, 5323-5335.
15. Cazzola, M., Della Porta, M.G. & Malcovati, L. (2013) The genetic basis of myelodysplasia and its clinical relevance. Blood, 122, 4021-4034.
16. Challen, G.A., Sun, D., Jeong, M., Luo, M., Jelinek, J., Berg, J.S., Bock, C., Vasanthakumar, A., Gu, H., Xi, Y., Liang, S., Lu, Y., Darlington, G.J., Meissner, A., Issa, J.P., Godley, L.A., Li, W. & Goodell, M.A. (2012) Dnmt3a is essential for hematopoietic stem cell differentiation. Nature Genetics, 44, 23-31.
17. Chaturvedi, A., Araujo Cruz, M.M., Jyotsana, N., Sharma, A., Yun, H., Gorlich, K., Wichmann, M., Schwarzer, A., Preller, M., Thol, F., Meyer, J., Haemmerle, R., Struys, E.A., Jansen, E.E., Modlich, U., Li, Z., Sly, L.M., Geffers, R., Lindner, R., Manstein, D.J., Lehmann, U., Krauter, J., Ganser, A. & Heuser, M. (2013) Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood, 122, 2877-2887.
18. Chen, M. & Manley, J.L. (2009) Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nature Reviews Molecular Cell Biology, 10, 741-754.
19. Chen, Q., Chen, Y., Bian, C., Fujiki, R. & Yu, X. (2013) TET2 promotes histone O-GlcNAcylation during gene transcription. Nature, 493, 561-564.
20. Chowdhury, R., Yeoh, K.K., Tian, Y.M., Hillringhaus, L., Bagg, E.A., Rose, N.R., Leung, I.K., Li, X.S., Woon, E.C., Yang, M., McDonough, M.A., King, O.N., Clifton, I.J., Klose, R.J., Claridge, T.D., Ratcliffe, P.J., Schofield, C.J. & Kawamura, A. (2011) The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Reports, 12, 463-469.
21. Damm, F., Kosmider, O., Gelsi-Boyer, V., Renneville, A., Carbuccia, N., Hidalgo-Curtis, C., Della Valle, V., Couronne, L., Scourzic, L., Chesnais, V., Guerci-Bresler, A., Slama, B., Beyne-Rauzy, O., Schmidt-Tanguy, A., Stamatoullas-Bastard, A., Dreyfus, F., Prebet, T., de Botton, S., Vey, N., Morgan, M.A., Cross, N.C., Preudhomme, C., Birnbaum, D., Bernard, O.A., Fontenay, M. & Groupe Francophone des, M. (2012) Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood, 119, 3211-3218.
22. Damm, F., Itzykson, R., Kosmider, O., Droin, N., Renneville, A., Chesnais, V., Gelsi-Boyer, V., de Botton, S., Vey, N., Preudhomme, C., Clavert, A., Delabesse, E., Park, S., Birnbaum, D., Fontenay, M., Bernard, O.A. & Solary, E. (2013) SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia, 27, 1401-1403.
23. Davies, C., Yip, B.H., Fernandez-Mercado, M., Woll, P.S., Agirre, X., Prosper, F., Jacobsen, S.E., Wainscoat, J.S., Pellagatti, A. & Boultwood, J. (2013) Silencing of ASXL1 impairs the granulomonocytic lineage potential of human CD34(+) progenitor cells. British Journal of Haematology, 160, 842-850.
24. Delhommeau, F., Dupont, S., Della Valle, V., James, C., Trannoy, S., Masse, A., Kosmider, O., Le Couedic, J.P., Robert, F., Alberdi, A., Lecluse, Y., Plo, I., Dreyfus, F.J., Marzac, C., Casadevall, N., Lacombe, C., Romana, S.P., Dessen, P., Soulier, J., Viguie, F., Fontenay, M., Vainchenker, W. & Bernard, O.A. (2009) Mutation in TET2 in myeloid cancers. New England Journal of Medicine, 360, 2289-2301.
25. Deneberg, S., Grovdal, M., Karimi, M., Jansson, M., Nahi, H., Corbacioglu, A., Gaidzik, V., Dohner, K., Paul, C., Ekstrom, T.J., Hellstrom-Lindberg, E. & Lehmann, S. (2010) Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia. Leukemia, 24, 932-941.
26. Deplus, R., Delatte, B., Schwinn, M.K., Defrance, M., Mendez, J., Murphy, N., Dawson, M.A., Volkmar, M., Putmans, P., Calonne, E., Shih, A.H., Levine, R.L., Bernard, O., Mercher, T., Solary, E., Urh, M., Daniels, D.L. & Fuks, F. (2013) TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS. EMBO Journal, 32, 645-655.
27. Dey, A., Seshasayee, D., Noubade, R., French, D.M., Liu, J., Chaurushiya, M.S., Kirkpatrick, D.S., Pham, V.C., Lill, J.R., Bakalarski, C.E., Wu, J., Phu, L., Katavolos, P., LaFave, L.M., Abdel-Wahab, O., Modrusan, Z., Seshagiri, S., Dong, K., Lin, Z., Balazs, M., Suriben, R., Newton, K., Hymowitz, S., Garcia-Manero, G., Martin, F., Levine, R.L. & Dixit, V.M. (2012) Loss of the tumor suppressor BAP1 causes myeloid transformation. Science, 337, 1541-1546.
28. Ernst, T., Chase, A.J., Score, J., Hidalgo-Curtis, C.E., Bryant, C., Jones, A.V., Waghorn, K., Zoi, K., Ross, F.M., Reiter, A., Hochhaus, A., Drexler, H.G., Duncombe, A., Cervantes, F., Oscier, D., Boultwood, J., Grand, F.H. & Cross, N.C. (2010) Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nature Genetics, 42, 722-726.
29. Fenaux, P., Mufti, G.J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., Gore, S.D., Seymour, J.F., Bennett, J.M., Byrd, J., Backstrom, J., Zimmerman, L., McKenzie, D., Beach, C., Silverman, L.R. & International Vidaza High-Risk MDS Survival Study Group. (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. The Lancet Oncology, 10, 223-232.
30. Fernandez-Mercado, M., Yip, B.H., Pellagatti, A., Davies, C., Larrayoz, M.J., Kondo, T., Perez, C., Killick, S., McDonald, E.J., Odero, M.D., Agirre, X., Prosper, F., Calasanz, M.J., Wainscoat, J.S. & Boultwood, J. (2012) Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics. PLoS ONE, 7, e42334.
31. Figueroa, M.E., Skrabanek, L., Li, Y., Jiemjit, A., Fandy, T.E., Paietta, E., Fernandez, H., Tallman, M.S., Greally, J.M., Carraway, H., Licht, J.D., Gore, S.D. & Melnick, A. (2009) MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood, 114, 3448-3458.
32. Figueroa, M.E., Abdel-Wahab, O., Lu, C., Ward, P.S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H.F., Tallman, M.S., Sun, Z., Wolniak, K., Peeters, J.K., Liu, W., Choe, S.E., Fantin, V.R., Paietta, E., Lowenberg, B., Licht, J.D., Godley, L.A., Delwel, R., Valk, P.J., Thompson, C.B., Levine, R.L. & Melnick, A. (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell, 18, 553-567.
33. Galm, O., Wilop, S., Luders, C., Jost, E., Gehbauer, G., Herman, J.G. & Osieka, R. (2005) Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia. Annals of Hematology, 84(Suppl. 1), 39-46.
34. Garcia-Manero, G., Kantarjian, H.M., Sanchez-Gonzalez, B., Yang, H., Rosner, G., Verstovsek, S., Rytting, M., Wierda, W.G., Ravandi, F., Koller, C., Xiao, L., Faderl, S., Estrov, Z., Cortes, J., O'Brien, S., Estey, E., Bueso-Ramos, C., Fiorentino, J., Jabbour, E. & Issa, J.P. (2006) Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood, 108, 3271-3279.
35. Gelsi-Boyer, V., Trouplin, V., Adelaide, J., Bonansea, J., Cervera, N., Carbuccia, N., Lagarde, A., Prebet, T., Nezri, M., Sainty, D., Olschwang, S., Xerri, L., Chaffanet, M., Mozziconacci, M.J., Vey, N. & Birnbaum, D. (2009) Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. British Journal of Haematology, 145, 788-800.
36. Graubert, T.A., Shen, D., Ding, L., Okeyo-Owuor, T., Lunn, C.L., Shao, J., Krysiak, K., Harris, C.C., Koboldt, D.C., Larson, D.E., McLellan, M.D., Dooling, D.J., Abbott, R.M., Fulton, R.S., Schmidt, H., Kalicki-Veizer, J., O'Laughlin, M., Grillot, M., Baty, J., Heath, S., Frater, J.L., Nasim, T., Link, D.C., Tomasson, M.H., Westervelt, P., DiPersio, J.F., Mardis, E.R., Ley, T.J., Wilson, R.K. & Walter, M.J. (2012) Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nature Genetics, 44, 53-57.
37. Guo, J.U., Su, Y., Zhong, C., Ming, G.L. & Song, H. (2011) Emerging roles of TET proteins and 5-hydroxymethylcytosines in active DNA demethylation and beyond. Cell Cycle, 10, 2662-2668.
38. Hollenbach, P.W., Nguyen, A.N., Brady, H., Williams, M., Ning, Y., Richard, N., Krushel, L., Aukerman, S.L., Heise, C. & MacBeth, K.J. (2010) A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS ONE, 5, e9001.
39. Inoue, D., Kitaura, J., Togami, K., Nishimura, K., Enomoto, Y., Uchida, T., Kagiyama, Y., Kawabata, K.C., Nakahara, F., Izawa, K., Oki, T., Maehara, A., Isobe, M., Tsuchiya, A., Harada, Y., Harada, H., Ochiya, T., Aburatani, H., Kimura, H., Thol, F., Heuser, M., Levine, R.L., Abdel-Wahab, O. & Kitamura, T. (2013) Myelodysplastic syndromes are induced by histone methylation-altering ASXL1 mutations. Journal of Clinical Investigation, 123, 4627-4640.
40. Issa, J.P. (2013) The myelodysplastic syndrome as a prototypical epigenetic disease. Blood, 121, 3811-3817.
41. Itzykson, R., Kosmider, O., Cluzeau, T., Mansat-De Mas, V., Dreyfus, F., Beyne-Rauzy, O., Quesnel, B., Vey, N., Gelsi-Boyer, V., Raynaud, S., Preudhomme, C., Ades, L., Fenaux, P., Fontenay, M. & Groupe Francophone des, M. (2011) Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia, 25, 1147-1152.
42. Jabbour, E., Garcia-Manero, G., Batty, N., Shan, J., O'Brien, S., Cortes, J., Ravandi, F., Issa, J.P. & Kantarjian, H. (2010) Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer, 116, 3830-3834.
43. Jabbour, E., Yee, K., Kropf, P., O'Connell, C., Stock, W., Tibes, R., Rizzieri, D., Walsh, K., Griffiths, E.A., Roboz, G.J., Savona, M., Ervin, T., Podoltsev, N.A., Pemmaraju, N., Daver, N., Garcia-Manero, G., Borthakur, G., Wierda, W.G., Ravandi, F., Cortes, J.E., Brandwein, J.M., Odenike, O., Feldman, E.J., Chung, W., Naim, S., Choy, G., Taverna, P., Hao, Y., Dimitrov, G., Azab, M. & Issa, J.-P. (2013) First clinical results of a randomized phase 2 study of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in adult patients with acute myeloid leukemia (AML). Blood, 122, 497.
44. Jerez, A., Sugimoto, Y., Makishima, H., Verma, A., Jankowska, A.M., Przychodzen, B., Visconte, V., Tiu, R.V., O'Keefe, C.L., Mohamedali, A.M., Kulasekararaj, A.G., Pellagatti, A., McGraw, K., Muramatsu, H., Moliterno, A.R., Sekeres, M.A., McDevitt, M.A., Kojima, S., List, A., Boultwood, J., Mufti, G.J. & Maciejewski, J.P. (2012) Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood, 119, 6109-6117.
45. Jiang, Y., Dunbar, A., Gondek, L.P., Mohan, S., Rataul, M., O'Keefe, C., Sekeres, M., Saunthararajah, Y. & Maciejewski, J.P. (2009) Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood, 113, 1315-1325.
46. Jost, E., Lin, Q., Weidner, C.I., Wilop, S., Hoffmann, M., Walenda, T., Schemionek, M., Herrmann, O., Zenke, M., Brummendorf, T.H., Koschmieder, S. & Wagner, W. (2013) Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia. Leukemia, doi: 10.1038/leu.2013.362.
47. Kamminga, L.M., Bystrykh, L.V., de Boer, A., Houwer, S., Douma, J., Weersing, E., Dontje, B. & de Haan, G. (2006) The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood, 107, 2170-2179.
48. Katoh, M. (2013) Functional and cancer genomics of ASXL family members. British Journal of Cancer, 109, 299-306.
49. Khan, S.N., Jankowska, A.M., Mahfouz, R., Dunbar, A.J., Sugimoto, Y., Hosono, N., Hu, Z., Cheriyath, V., Vatolin, S., Przychodzen, B., Reu, F.J., Saunthararajah, Y., O'Keefe, C., Sekeres, M.A., List, A.F., Moliterno, A.R., McDevitt, M.A., Maciejewski, J.P. & Makishima, H. (2013) Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. Leukemia, 27, 1301-1309.
50. Ko, M., Huang, Y., Jankowska, A.M., Pape, U.J., Tahiliani, M., Bandukwala, H.S., An, J., Lamperti, E.D., Koh, K.P., Ganetzky, R., Liu, X.S., Aravind, L., Agarwal, S., Maciejewski, J.P. & Rao, A. (2010) Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature, 468, 839-843.
51. Ko, M., Bandukwala, H.S., An, J., Lamperti, E.D., Thompson, E.C., Hastie, R., Tsangaratou, A., Rajewsky, K., Koralov, S.B. & Rao, A. (2011) Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proceedings of the National Academy of Sciences of the United States of America, 108, 14566-14571.
52. Kosmider, O., Gelsi-Boyer, V., Slama, L., Dreyfus, F., Beyne-Rauzy, O., Quesnel, B., Hunault-Berger, M., Slama, B., Vey, N., Lacombe, C., Solary, E., Birnbaum, D., Bernard, O.A. & Fontenay, M. (2010) Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia, 24, 1094-1096.
53. Kulasekararaj, A.G., Mohamedali, A.M., Smith, A.E., Lea, N.C., Kizilors, A., Abdallah, A., Nasser, E.E., Mian, S.A., Yiu, R., Gaken, J., Pomplun, S., Jiang, J., Gaymes, T.J., Pasipanodya, P., Hayden, J., Ireland, R.M., Lim, Z., Ho, A.Y., Marsh, J.C.W. & Mufti, G.J. (2010) Polycomb complex group gene mutations and their prognostic relevance in 5-azacitidine treated myelodysplastic syndrome patients. Blood (ASH Annual Meeting Abstracts), 116, 125.
54. Lee, Y.G., Kim, I., Yoon, S.S., Park, S., Cheong, J.W., Min, Y.H., Lee, J.O., Bang, S.M., Yi, H.G., Kim, C.S., Park, Y., Kim, B.S., Mun, Y.C., Seong, C.M., Park, J., Lee, J.H., Kim, S.Y., Lee, H.G., Kim, Y.K., Kim, H.J. & Korean Society of Haematology AML/MDS Working Party. (2013) Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes. British Journal of Haematology, 161, 339-347.
55. Li, Z., Cai, X., Cai, C.L., Wang, J., Zhang, W., Petersen, B.E., Yang, F.C. & Xu, M. (2011) Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood, 118, 4509-4518.
56. Li, K.K., Luo, L.F., Shen, Y., Xu, J., Chen, Z. & Chen, S.J. (2013) DNA methyltransferases in hematologic malignancies. Seminars in Hematology, 50, 48-60.
57. Long, J.C. & Caceres, J.F. (2009) The SR protein family of splicing factors: master regulators of gene expression. The Biochemical Journal, 417, 15-27.
58. Lu, C., Ward, P.S., Kapoor, G.S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C.R., Khanin, R., Figueroa, M.E., Melnick, A., Wellen, K.E., O'Rourke, D.M., Berger, S.L., Chan, T.A., Levine, R.L., Mellinghoff, I.K. & Thompson, C.B. (2012) IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature, 483, 474-478.
59. Lund, K., Adams, P.D. & Copland, M. (2014) EZH2 in normal and malignant hematopoiesis. Leukemia, 28, 44-49.
60. Makishima, H., Visconte, V., Sakaguchi, H., Jankowska, A.M., Abu Kar, S., Jerez, A., Przychodzen, B., Bupathi, M., Guinta, K., Afable, M.G., Sekeres, M.A., Padgett, R.A., Tiu, R.V. & Maciejewski, J.P. (2012) Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood, 119, 3203-3210.
61. Malcovati, L., Papaemmanuil, E., Bowen, D.T., Boultwood, J., Della Porta, M.G., Pascutto, C., Travaglino, E., Groves, M.J., Godfrey, A.L., Ambaglio, I., Galli, A., Da Via, M.C., Conte, S., Tauro, S., Keenan, N., Hyslop, A., Hinton, J., Mudie, L.J., Wainscoat, J.S., Futreal, P.A., Stratton, M.R., Campbell, P.J., Hellstrom-Lindberg, E., Cazzola, M., Chronic Myeloid Disorders Working Group of the International Cancer Genome, C. & of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie, M. (2011) Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood, 118, 6239-6246.
62. Mian, S.A., Smith, A.E., Kulasekararaj, A.G., Kizilors, A., Mohamedali, A.M., Lea, N.C., Mitsopoulos, K., Ford, K., Nasser, E., Seidl, T. & Mufti, G.J. (2013) Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome. Haematologica, 98, 1058-1066.
63. Mohamedali, A.M., Smith, A.E., Gaken, J., Lea, N.C., Mian, S.A., Westwood, N.B., Strupp, C., Gattermann, N., Germing, U. & Mufti, G.J. (2009) Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. Journal of Clinical Oncology, 27, 4002-4006.
64. Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M.E., Vasanthakumar, A., Patel, J., Zhao, X., Perna, F., Pandey, S., Madzo, J., Song, C., Dai, Q., He, C., Ibrahim, S., Beran, M., Zavadil, J., Nimer, S.D., Melnick, A., Godley, L.A., Aifantis, I. & Levine, R.L. (2011) Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell, 20, 11-24.
65. Morey, L. & Helin, K. (2010) Polycomb group protein-mediated repression of transcription. Trends in Biochemical Sciences, 35, 323-332.
66. Muller, J. & Verrijzer, P. (2009) Biochemical mechanisms of gene regulation by polycomb group protein complexes. Current Opinion in Genetics & Development, 19, 150-158.
67. Muto, T., Sashida, G., Oshima, M., Wendt, G.R., Mochizuki-Kashio, M., Nagata, Y., Sanada, M., Miyagi, S., Saraya, A., Kamio, A., Nagae, G., Nakaseko, C., Yokote, K., Shimoda, K., Koseki, H., Suzuki, Y., Sugano, S., Aburatani, H., Ogawa, S. & Iwama, A. (2013) Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. Journal of Experimental Medicine, 210, 2627-2639.
68. Nagata, Y., Sanada, M., Kon, A., Yoshida, K., Shiraishi, Y., Sato-Otsubo, A., Mori, H., Ishiyama, K., Sakata-Yanagimoto, M., Obara, N., Nagasaki, M., Miyawaki, S., Chiba, S., Miyano, S., Yung, S.L., Koeffler, H.P. & Ogawa, S. (2011) Mutational spectrum analysis of interesting correlation and interrelationship between RNA splicing pathway and commonly targeted genes in myelodysplastic syndrome. Blood (ASH Annual Meeting Abstracts), 118, 273.
69. Negrotto, S., Ng, K.P., Jankowska, A.M., Bodo, J., Gopalan, B., Guinta, K., Mulloy, J.C., Hsi, E., Maciejewski, J. & Saunthararajah, Y. (2012) CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors. Leukemia, 26, 244-254.
70. Neri, F., Krepelova, A., Incarnato, D., Maldotti, M., Parlato, C., Galvagni, F., Matarese, F., Stunnenberg, H.G. & Oliviero, S. (2013) Dnmt3L antagonizes DNA methylation at bivalent promoters and favors DNA methylation at gene bodies in ESCs. Cell, 155, 121-134.
71. Nikoloski, G., Langemeijer, S.M., Kuiper, R.P., Knops, R., Massop, M., Tonnissen, E.R., van der Heijden, A., Scheele, T.N., Vandenberghe, P., de Witte, T., van der Reijden, B.A. & Jansen, J.H. (2010) Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nature Genetics, 42, 665-667.
72. Orford, K., Kharchenko, P., Lai, W., Dao, M.C., Worhunsky, D.J., Ferro, A., Janzen, V., Park, P.J. & Scadden, D.T. (2008) Differential H3K4 methylation identifies developmentally poised hematopoietic genes. Developmental Cell, 14, 798-809.
73. Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J.S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., Godfrey, A.L., Rapado, I., Cvejic, A., Rance, R., McGee, C., Ellis, P., Mudie, L.J., Stephens, P.J., McLaren, S., Massie, C.E., Tarpey, P.S., Varela, I., Nik-Zainal, S., Davies, H.R., Shlien, A., Jones, D., Raine, K., Hinton, J., Butler, A.P., Teague, J.W., Baxter, E.J., Score, J., Galli, A., Della Porta, M.G., Travaglino, E., Groves, M., Tauro, S., Munshi, N.C., Anderson, K.C., El-Naggar, A., Fischer, A., Mustonen, V., Warren, A.J., Cross, N.C., Green, A.R., Futreal, P.A., Stratton, M.R., Campbell, P.J. & Chronic Myeloid Disorders Working Group of the International Cancer Genome, C. (2011) Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. New England Journal of Medicine, 365, 1384-1395.
74. Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van Loo, P., Yoon, C.J., Ellis, P., Wedge, D.C., Pellagatti, A., Shlien, A., Groves, M.J., Forbes, S.A., Raine, K., Hinton, J., Mudie, L.J., McLaren, S., Hardy, C., Latimer, C., Della Porta, M.G., O'Meara, S., Ambaglio, I., Galli, A., Butler, A.P., Walldin, G., Teague, J.W., Quek, L., Sternberg, A., Gambacorti-Passerini, C., Cross, N.C., Green, A.R., Boultwood, J., Vyas, P., Hellstrom-Lindberg, E., Bowen, D., Cazzola, M., Stratton, M.R., Campbell, P.J. & Chronic Myeloid Disorders Working Group of the International Cancer Genome, C. (2013) Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood, 122, 3616-3627; quiz 3699.
75. Patnaik, M.M., Hanson, C.A., Hodnefield, J.M., Lasho, T.L., Finke, C.M., Knudson, R.A., Ketterling, R.P., Pardanani, A. & Tefferi, A. (2012) Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Leukemia, 26, 101-105.
76. Prebet, T., Gore, S.D., Sun, Z., Greenberg, P.L., Juckett, M., Malick, L., Smith, M.R., Paietta, E., Czader, M., Gabrilove, J., Erba, H.P. & Tallman, M.S. (2010) Prolonged administration of azacitidine with or without entinostat increases rate of hematologic normalization for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US leukemia intergroup trial E1905. Blood (ASH Annual Meeting Abstracts), 116, 601.
77. Qiu, J., Lin, L., Xu, Y., Thol, F., Monterroza, D.D., Dekelver, R., Chen, L., Heuser, M., Fu, X.-D. & Zhang, D.-E. (2013) SRSF2 is essential for hematopoiesis and its mutations dysregulate alternative RNA splicing in MDS. Blood, 122, 261.
78. Quintas-Cardama, A., Kantarjian, H.M., Ravandi, F., Foudray, C., Pemmaraju, N., Kadia, T.M., Borthakur, G., Daver, N.G., Faderl, S., Jabbour, E., Cortes, J.E. & Garcia-Manero, G. (2012) Very high rates of clinical and cytogenetic response with the combination of the histone deacetylase inhibitor pracinostat (SB939) and 5-azacitidine in high-risk myelodysplastic syndrome. Blood (ASH Annual Meeting Abstracts), 120, 3821.
79. Quivoron, C., Couronne, L., Della Valle, V., Lopez, C.K., Plo, I., Wagner-Ballon, O., Do Cruzeiro, M., Delhommeau, F., Arnulf, B., Stern, M.H., Godley, L., Opolon, P., Tilly, H., Solary, E., Duffourd, Y., Dessen, P., Merle-Beral, H., Nguyen-Khac, F., Fontenay, M., Vainchenker, W., Bastard, C., Mercher, T. & Bernard, O.A. (2011) TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell, 20, 25-38.
80. Rocquain, J., Carbuccia, N., Trouplin, V., Raynaud, S., Murati, A., Nezri, M., Tadrist, Z., Olschwang, S., Vey, N., Birnbaum, D., Gelsi-Boyer, V. & Mozziconacci, M.J. (2010) Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer, 10, 401.
81. Rogers, H.J., Tabarroki, A., Zhang, L., Parker, Y., Hasrouni, E., Mahfouz, R.Z., Ebrahem, Q., Isono, K., Koseki, H., Advani, A.S., Saunthararajah, Y., Sekeres, M.A., Lindner, D., Barnard, J. & Tiu, R.V. (2013) Splicing factor 3b subunit 1 (SF3B1) heterozygous mice manifest a hematologic phenotype similar to low risk myelodysplastic syndromes with ring sideroblasts. Blood (ASH Annual Meeting Abstracts), 122, 259.
82. Shen, L., Kantarjian, H., Guo, Y., Lin, E., Shan, J., Huang, X., Berry, D., Ahmed, S., Zhu, W., Pierce, S., Kondo, Y., Oki, Y., Jelinek, J., Saba, H., Estey, E. & Issa, J.P. (2010) DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. Journal of Clinical Oncology, 28, 605-613.
83. Silva, G., Cardoso, B.A., Belo, H. & Almeida, A.M. (2013) Vorinostat induces apoptosis and differentiation in myeloid malignancies: genetic and molecular mechanisms. PLoS ONE, 8, e53766.
84. Smith, A.E., Mohamedali, A.M., Kulasekararaj, A., Lim, Z., Gaken, J., Lea, N.C., Przychodzen, B., Mian, S.A., Nasser, E.E., Shooter, C., Westwood, N.B., Strupp, C., Gattermann, N., Maciejewski, J.P., Germing, U. & Mufti, G.J. (2010) Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood, 116, 3923-3932.
85. Solary, E., Bernard, O.A., Tefferi, A., Fuks, F. & Vainchenker, W. (2014) The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia, 28, 485-496.
86. Thol, F., Weissinger, E.M., Krauter, J., Wagner, K., Damm, F., Wichmann, M., Gohring, G., Schumann, C., Bug, G., Ottmann, O., Hofmann, W.K., Schlegelberger, B., Ganser, A. & Heuser, M. (2010) IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica, 95, 1668-1674.
87. Thol, F., Friesen, I., Damm, F., Yun, H., Weissinger, E.M., Krauter, J., Wagner, K., Chaturvedi, A., Sharma, A., Wichmann, M., Gohring, G., Schumann, C., Bug, G., Ottmann, O., Hofmann, W.K., Schlegelberger, B., Heuser, M. & Ganser, A. (2011a) Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. Journal of Clinical Oncology, 29, 2499-2506.
88. Thol, F., Winschel, C., Ludeking, A., Yun, H., Friesen, I., Damm, F., Wagner, K., Krauter, J., Heuser, M. & Ganser, A. (2011b) Rare occurrence of DNMT3A mutations in myelodysplastic syndromes. Haematologica, 96, 1870-1873.
89. Thol, F., Kade, S., Schlarmann, C., Loffeld, P., Morgan, M., Krauter, J., Wlodarski, M.W., Kolking, B., Wichmann, M., Gorlich, K., Gohring, G., Bug, G., Ottmann, O., Niemeyer, C.M., Hofmann, W.K., Schlegelberger, B., Ganser, A. & Heuser, M. (2012) Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood, 119, 3578-3584.
90. Toyota, M., Kopecky, K.J., Toyota, M.O., Jair, K.W., Willman, C.L. & Issa, J.P. (2001) Methylation profiling in acute myeloid leukemia. Blood, 97, 2823-2829.
91. Traina, F., Visconte, V., Elson, P., Tabarroki, A., Jankowska, A.M., Hasrouni, E., Sugimoto, Y., Szpurka, H., Makishima, H., O'Keefe, C.L., Sekeres, M.A., Advani, A.S., Kalaycio, M., Copelan, E.A., Saunthararajah, Y., Olalla Saad, S.T., Maciejewski, J.P. & Tiu, R.V. (2014) Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia, 28, 78-87.
92. Verma, A., Odchimar-Reissig, R., Feldman, E.J., Navada, S.C., Demakos, E.P., Baer, M.R., Najfeld, V., Sparano, J.A. & Piekarz, R. (2013) A phase II trial of epigenetic modulators vorinostat in combination with azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS): initial results of study 6898 of the New York Cancer Consortium. Blood, 122, 386.
93. Vire, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C., Morey, L., Van Eynde, A., Bernard, D., Vanderwinden, J.M., Bollen, M., Esteller, M., Di Croce, L., de Launoit, Y. & Fuks, F. (2006) The Polycomb group protein EZH2 directly controls DNA methylation. Nature, 439, 871-874.
94. Wahl, M.C., Will, C.L. & Luhrmann, R. (2009) The spliceosome: design principles of a dynamic RNP machine. Cell, 136, 701-718.
95. Walter, M.J., Ding, L., Shen, D., Shao, J., Grillot, M., McLellan, M., Fulton, R., Schmidt, H., Kalicki-Veizer, J., O'Laughlin, M., Kandoth, C., Baty, J., Westervelt, P., DiPersio, J.F., Mardis, E.R., Wilson, R.K., Ley, T.J. & Graubert, T.A. (2011) Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia, 25, 1153-1158.
96. Wang, J., Li, Z., He, Y., Pan, F., Chen, S., Rhodes, S., Nguyen, L., Yuan, J., Jiang, L., Yang, X., Weeks, O., Liu, Z., Zhou, J., Ni, H., Cai, C.L., Xu, M. & Yang, F.C. (2014) Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice. Blood, 123, 541-553.
97. Ward, P.S., Patel, J., Wise, D.R., Abdel-Wahab, O., Bennett, B.D., Coller, H.A., Cross, J.R., Fantin, V.R., Hedvat, C.V., Perl, A.E., Rabinowitz, J.D., Carroll, M., Su, S.M., Sharp, K.A., Levine, R.L. & Thompson, C.B. (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell, 17, 225-234.
98. Wei, Y., Chen, R., Dimicoli, S., Bueso-Ramos, C., Neuberg, D., Pierce, S., Wang, H., Yang, H., Jia, Y., Zheng, H., Fang, Z., Nguyen, M., Ganan-Gomez, I., Ebert, B., Levine, R., Kantarjian, H. & Garcia-Manero, G. (2013a) Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells. Leukemia, 27, 2177-2186.
99. Wei, Y., Dimicoli, S., Bueso-Ramos, C., Chen, R., Yang, H., Neuberg, D., Pierce, S., Jia, Y., Zheng, H., Wang, H., Wang, X., Nguyen, M., Wang, S.A., Ebert, B., Bejar, R., Levine, R., Abdel-Wahab, O., Kleppe, M., Ganan-Gomez, I., Kantarjian, H. & Garcia-Manero, G. (2013b) Toll-like receptor alterations in myelodysplastic syndrome. Leukemia, 27, 1832-1840.
100. Wilop, S., Fernandez, A.F., Jost, E., Herman, J.G., Brummendorf, T.H., Esteller, M. & Galm, O. (2011) Array-based DNA methylation profiling in acute myeloid leukaemia. British Journal of Haematology, 155, 65-72.
101. Wu, S.J., Kuo, Y.Y., Hou, H.A., Li, L.Y., Tseng, M.H., Huang, C.F., Lee, F.Y., Liu, M.C., Liu, C.W., Lin, C.T., Chen, C.Y., Chou, W.C., Yao, M., Huang, S.Y., Ko, B.S., Tang, J.L., Tsay, W. & Tien, H.F. (2012) The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood, 120, 3106-3111.
102. Wu, S.J., Tang, J.L., Lin, C.T., Kuo, Y.Y., Li, L.Y., Tseng, M.H., Huang, C.F., Lai, Y.J., Lee, F.Y., Liu, M.C., Liu, C.W., Hou, H.A., Chen, C.Y., Chou, W.C., Yao, M., Huang, S.Y., Ko, B.S., Tsay, W. & Tien, H.F. (2013) Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression. American Journal of Hematology, 88, E277-E282.
103. Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.H., Ito, S., Yang, C., Wang, P., Xiao, M.T., Liu, L.X., Jiang, W.Q., Liu, J., Zhang, J.Y., Wang, B., Frye, S., Zhang, Y., Xu, Y.H., Lei, Q.Y., Guan, K.L., Zhao, S.M. & Xiong, Y. (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell, 19, 17-30.
104. Yang, H., Bueso-Ramos, C., Dinardo, C., Estecio, M.R., Davanlou, M., Geng, Q.R., Fang, Z., Nguyen, M., Pierce, S., Wei, Y., Parmar, S., Cortes, J., Kantarjian, H. & Garcia-Manero, G. (2013) Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia, doi: 10.1038/leu.2013.355.
105. Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., Chalkidis, G., Suzuki, Y., Shiosaka, M., Kawahata, R., Yamaguchi, T., Otsu, M., Obara, N., Sakata-Yanagimoto, M., Ishiyama, K., Mori, H., Nolte, F., Hofmann, W.K., Miyawaki, S., Sugano, S., Haferlach, C., Koeffler, H.P., Shih, L.Y., Haferlach, T., Chiba, S., Nakauchi, H., Miyano, S. & Ogawa, S. (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature, 478, 64-69.